Optimizing the dose of post-transplant cyclophosphamide for stem cell transplant patients
Official title: Optimizing the dosing of post-transplantation cyclophosphamide for peripheral blood stem cell transplantation
Funded at Fred Hutchinson Cancer Center · NIH-11451114 · Data updated 2026-11-12
Researchers are testing the best dose of a drug given after stem cell transplants to reduce complications and improve recovery for people who need donor stem cells.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | September 1, 2026 |
| Project end | August 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $695,155 |
| NIH project number | 1U01CA303465-01A1 |
| Project ID | NIH-11451114 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients undergoing allogeneic hematopoietic cell transplantation who may receive post-transplant cyclophosphamide, including those with haploidentical or matched donors.
✕Less likely to help
Patients receiving transplants with standard care where the new dosing offers no added advantage or those not receiving PTCy.
What this research studies
Allogeneic stem cell transplantation can cure some blood diseases but is limited by graft-versus-host disease. This work focuses on identifying the optimal dose of post-transplant cyclophosphamide to prevent GVHD while reducing toxicity and supporting immune recovery. The project builds on prior trials showing different dosing may balance safety and effectiveness and will test 25 mg/kg/day in ongoing trials to refine care. The goal is to expand safe access to transplant options, including partial or mismatched donor transplants, with better patient outcomes.
Why it matters
Potential benefit: Finding the best PTCy dose could lower GVHD risk and toxicity, speeding recovery and broadening donor options for patients.
How similar studies have gone: Prior phase I/II studies suggest intermediate PTCy doses can prevent GVHD with favorable safety and recovery signals, guiding this optimization effort.
Where this research is happening
-
Fred Hutchinson Cancer Center
Seattle, United States Active
Researchers
- Principal investigator: Mielcarek, Marco B — Fred Hutchinson Cancer Center
- Study coordinator: Mielcarek, Marco B
Related research
Other NIH-funded projects on the same topics.
-
How brain glia prune neuron fragments in a worm model
Researchers study how brain support cells called glia remove pieces of living neurons in a tiny worm to learn about brain aging and diseases like Alzheimer's.
-
Understanding and Targeting Lineage Plasticity in Prostate Cancer with Genomic-Based Neoadjuvant Therapy
A broad research program at Fred Hutchinson Cancer Center is exploring how aggressive prostate cancers change their cell states in response to therapy and how to block these changes.
-
Personalized cancer drug testing on patient tumor cells
Aiming to test many FDA-approved cancer drugs on a patient’s own tumor cells to identify effective options when standard therapies fail.
-
MOSAAIC: Using health records to track heart disease in Asian American Communities
A big, dedicated effort is testing whether electronic health records can more quickly and accurately track heart and blood vessel problems in Asian American populations.
-
Targeting gut microbes to prevent progression to multiple myeloma
Researchers are testing how specific gut bacteria might trigger immune changes linked to early blood cancer stages and whether targeting these microbes could help prevent progression to multiple myeloma.
-
eDyNAmiC: Understanding extrachromosomal DNA in cancer and how it drives aggressiveness
A cancer research project at Fred Hutchinson Cancer Center is studying abnormal circular DNA pieces (ecDNA) that help cancers grow and resist treatment, with the aim of finding ways to help patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.